Navigation Links
ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:9/23/2009

er on the milestones needed to build a strong, successful and profitable Company."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 /PRNewswire/ --Research and Markets ( http://www.researchandmarkets.com/research/vzcw2v/americas_clinical ... Chemistry Analyzer Market by Product, by End-Users - Forecast to ... Clinical Chemistry Analyzers market is estimated to grow at a ... the U.S., Canada , Mexico ... Americas (RoA) are covered in this report. The ...
(Date:5/1/2015)... 1, 2015 Following yesterday,s release of Center for ... are five things you need to know: ... is unique among government programs. ... different than other parts of Medicare and other government programs ... bids to offer prescription drug benefits to enrollees. , ...
(Date:5/1/2015)... and Markets ( http://www.researchandmarkets.com/research/pjbxjd/us_aco_it ) has announced ... Outlook 2018" report to their offering. ... ACO would grow at a CAGR of 22% during ... has been studied on three main grounds viz. spending ... Our research provides current market estimation and forecast till ...
Breaking Medicine Technology:Americas Clinical Chemistry Analyzer (Semi-Automated Clinical Chemistry and Fully-Automated Clinical Chemistry) Market - Forecast to 2019 25 Things to Know About the CMS Part D Data Release 25 Things to Know About the CMS Part D Data Release 3United States ACO IT Spending Outlook 2014-2018 2
... March 3, 2011 Dynatronics Corporation (Nasdaq: ... FirstChoice Cooperative, a group purchasing organization (GPO) headquartered in ... 20,000 members nationwide.  The three-year agreement with FirstChoice is ... the third GPO contract signed in the past two ...
... MASI ) today announced that its management is ... Conference at the Ritz-Carlton in Laguna Niguel, Calif. on Tuesday, ... of the presentation will be available on the Masimo website ... be available following the live presentation. ...
Cached Medicine Technology:Dynatronics Signs Third GPO Contract in Two Months 2Masimo to Present at the Roth Growth Stock Conference 2
(Date:5/2/2015)... 02, 2015 As a nonsurgical ... of the face, neck and décolleté, radiofrequency energy ... real potential for the success of vulvovaginal rejuvenation. ... Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory ... concluded that ThermiGyn’s temperature controlled radio frequency, specifically ...
(Date:5/1/2015)... Frisco, Texas (PRWEB) May 02, 2015 ... Frisco, Texas, is proud to announce the addition of ... Jen Widerstrom is a life long athlete, growing up ... fitness passion after college by becoming a personal trainer ... since been the face of several TV shows highlighting ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious 2015 ... flagship nutritional supplement, Liquid BioCell™ Life, and the relaunch ... logo, new packaging, new products, and new messaging. ... and promote programs that serve as examples of direct ... International for their outstanding accomplishments and contributions to direct ...
(Date:5/1/2015)... May 01, 2015 TROY Healthcare Solutions ... Southeast Regional User Group (RUG) Conference in Atlanta, GA ... Regional User Group Conference provides a forum for client-to-client ... support all aspects of electronic medical record operations, as ... software applications. , In addition to sponsoring the event, ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... Serena Gordon HealthDay Reporter , THURSDAY, May 19 ... is especially tough, say allergy experts. "Everyone always ... worst year ever for allergies," said Dr. David Rosenstreich, director ... in New York City. But this year those complaints ...
... from the American Cancer Society details cancer control efforts and ... contribute to cancer mortality. Increasing rates of obesity observed since ... decade, particularly among women and girls, but nearly one in ... Vaccination against the virus that causes cervical cancer is up, ...
... Theurer Cancer Center at Hackensack University Medical Center,s Cutaneous Malignancies ... skin cancer screening event on Thursday, June 2 from 10am ... cancer prevention and offer free skin cancer screenings by appointment ... be a devastating disease, but when caught early it is ...
... of studies on whether moderate exercise can curb the ... an apparent contradiction: it seems to work in short-term, ... treatment trials. A new study may explain why and ... suggested in the results of research led by David ...
... Clinical Oncology (ASCO) today highlighted several studies in a ... posted online at www.asco.org in advance of ASCO,s 47th ... other major studies will be released in on-site press ... meeting, which is expected to draw approximately 30,000 cancer ...
... This release is available in German . ... future, doctors will be able to take a closer look at ... a few fractions of a second. It examines to a resolution ... images so quickly that the results are not blurred even if ...
Cached Medicine News:Health News:Springtime and the Sneezin' Is Easy 2Health News:Springtime and the Sneezin' Is Easy 3Health News:Report outlines successes, challenges in cancer prevention efforts 2Health News:Report outlines successes, challenges in cancer prevention efforts 3Health News:Exercise helps women fight smoking cravings, but effect is short-lived 2Health News:ASCO releases studies from upcoming annual meeting 2Health News:ASCO releases studies from upcoming annual meeting 3Health News:Microscope -- handy, quick and flat 2Health News:Microscope -- handy, quick and flat 3
Angled insertion forcep used for the Hydroview lens. Manufactured in titanium....
Titanium. Curved 18 mm shafts with 1.5 wide grasping tip. Flat, serrated cross action handle with dull finish....
30 degree angled tip with 45 mm tip opening. Made with lock. Manufactured in titanium....
Straight 25 gauge shaft with angled tip and sliding inner shaft. Shaft holds the proximal loop against the angled tip while handle in the normal state. Squeeze type handle with dull finish....
Medicine Products: